Cancer de l'ovaire Canada logo
EN /

FR

RSVP pour Speaker Series | HRD testing in ovarian cancer

The Ovarian Cancer Canada Speaker Series features experts from across the country discussing a wide range of topics for people living with ovarian cancer and their families and friends.

Join us on Thursday, February 12 from 6:30 p.m. ET - 8:00 p.m. ET for 'HRD testing in ovarian cancer: What patients need to know'

Join Ovarian Cancer Canada as we explore homologous recombination deficiency (HRD) testing – a key tool that can help guide treatment decisions for people living with ovarian cancer.

In this session, experts in gynecologic pathology, gynecologic oncology, and advocacy will explain:

  • What HRD is and why it’s important for ovarian cancer
  • How HRD testing works and what your results may mean
  • How HRD testing can help guide treatment decisions
  • Our advocacy efforts to make HRD testing accessible nationwide

Whether you’re newly diagnosed, in treatment, supporting a loved one, or simply wanting to learn more, this webinar will offer clear, patient-focused information to inform and empower you.


Veuillez répondre aux questions supplémentaires suivantes pour nous aider à préparer l'événement.

*1.


*2.


*3.